An impressive data set on progressive free survival (PFS) demonstrated by Roche's IMpower150 study in non-squamous non-small cell lung cancer (NSCLC) was nonetheless overshadowed at the American Association for Cancer Research (AACR) meeting April 16 by rival trial presentations - and observers say the jury will remain out about IMpower150's four-drug regime until overall survival data is presented later this year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?